AIOSYN
18.9.2023 14:10:34 CEST | Business Wire | Press release
Aiosyn, a medical software company specializing in AI-powered pathology solutions, has announced the release of an AI kidney suite designed to advance research in the field of renal disease. Leveraging cutting-edge deep learning technology, this innovative solution provides biopharma and research organizations with powerful tools for analyzing kidney structures and quantifying lesions that impact kidney health. Aiosyn’s kidney AI suite marks yet another significant milestone for the company, following the recent launch of Aiosyn Mitosis Research.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230918761099/en/
Healthy and sclerotic glomeruli in a renal biopsy are identified with Aiosyn’s solutions powered by AI. (Photo: Business Wire)
Patrick de Boer, CEO of Aiosyn: "The platform will enable researchers to identify new and existing CKD biomarkers to study specific patient subgroups. With these new algorithms and AI capabilities we provide CKD researchers with new tools to complement existing biomarker projects and help to advance CKD precision medicine."
With 850 million people worldwide affected by kidney disease (1) and Chronic Kidney Disease (CKD) projected to become the fifth leading cause of death by 2040 (2), there is an urgent need for improved diagnosis and treatment. Aiosyn's kidney AI suite utilizes AI-powered computational pathology algorithms to objectively quantify kidney lesion scores, offering an opportunity to enhance reproducibility and accelerate drug development. The platform addresses the limitations of the Banff classification currently used in renal biopsy analysis, which suffers from observer variability and relies on qualitative assessments.
Aiosyn’s kidney AI suite facilitates the identification and characterization of pathological processes, presenting a promising avenue for substantial improvements in CKD research and clinical trials. Alongside its kidney AI platform, Aiosyn is actively developing advanced deep learning algorithms for the detection of cancer biomarkers.
About Aiosyn
Aiosyn is a Dutch medical software company that develops AI-powered pathology solutions for cancer and kidney diseases. Aiosyn’s solutions are integrated into standard pathology workflows. The Aiosyn team has been built upon 20+ years of research experience in the field of pathology and is rooted in the pathology practice.
Sources
- Jager, K. J., Kovesdy, C., Langham, R., Rosenberg, M., Jha, V., & Zoccali, C. (2019). A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases. Nephrology Dialysis Transplantation, 34(11), 1803-1805.
- Foreman, K. J., Marquez, N., Dolgert, A., Fukutaki, K., Fullman, N., McGaughey, M., ... & Murray, C. J. (2018). Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. The Lancet, 392(10159), 2052-2090.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230918761099/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stonebranch is Again Named a Leader in the 2026 Gartner® Magic Quadrant™ for Service Orchestration and Automation Platforms (SOAPs)10.8.2026 17:00:00 CEST | Press release
Gartner recognizes Stonebranch as a Leader for the third consecutive year based on Completeness of Vision and Ability to Execute. Stonebranch, a leading provider of service orchestration and automation solutions, today announced that it has once again been positioned by Gartner as a Leader in the Magic Quadrant for Service Orchestration and Automation Platforms (SOAPs) for its offering, Universal Automation Center™ (UAC).1 “We’re pleased to be recognized as a Leader for the third year in a row,” said Giuseppe Damiani, CEO at Stonebranch. “To us, this recognition reflects our advancements in helping enterprises orchestrate increasingly complex IT operations with confidence. As organizations modernize their automation strategies and adopt AI, UAC provides the centralized orchestration control plane required to unify traditional automation with AI models and agentic systems. With built-in capabilities like Robi AI, UAC’s agentic copilot, we’re making it easier than ever for teams to build
Frontgrade Expands Huntsville Presence with Advanced R&D Center Supporting Next-Generation Space and Defense Missions10.8.2026 16:09:00 CEST | Press release
New facility in Cummings Research Park brings engineering closer to customers while advancing mission processing technologies and strengthening Frontgrade's long-term investment in Huntsville Frontgrade Technologies ("Frontgrade"), a leading provider of mission-critical electronics and integrated technologies, today announced the opening of its eighth U.S. location in Huntsville, Alabama. Located in Cummings Research Park, the new Advanced Research & Development Center will accelerate the development of next-generation mission processing technologies supporting critical space, defense, intelligence, and national security missions. The Huntsville center expands Frontgrade's engineering capabilities while placing research teams closer to customers, government organizations, industry partners, and leading academic institutions. By working within one of the nation's premier aerospace and defense ecosystems, Frontgrade will accelerate technology development, strengthen customer collaboratio
Brightfin Appoints Preeti Shukla as Chief Product and AI Officer10.8.2026 15:00:00 CEST | Press release
Enterprise AI SaaS leader to accelerate Brightfin's AI-Native platform for IT financial management Brightfin, the only IT Financial Management (ITFM) and Technology Expense Management solution built natively on ServiceNow, today announced the appointment of Preeti Shukla as Chief Product and AI Officer (CPAIO). In this newly created role, Shukla will lead product strategy and artificial intelligence across the Brightfin platform, advancing the company's mission to make every technology decision grounded in financial truth, operational clarity, and intelligent automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260810283143/en/ Preeti Shukla, CPAIO of Brightfin Shukla brings two decades of experience building and scaling customer-facing, enterprise-grade B2B SaaS, fintech, and marketplace products across Fortune 100 companies and high-growth startups, including leadership roles at Workday and Oracle. A recognized autho
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration10.8.2026 12:00:00 CEST | Press release
Clinical collaboration enables novel combinations of select BeOne oncology assets with four Revolution Medicines clinical-stage RAS(ON) inhibitors for RAS-addicted cancersRegional rights agreement provides BeOne with exclusive development and commercialization rights to four Revolution Medicines clinical assets in select Asian markets BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS(ON) inhibitors, and a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets. Clinical
OpenGate Capital to Acquire Maersk Training, the Global Safety Training and Gas-Safety Services Business of Maersk10.8.2026 08:00:00 CEST | Press release
OpenGate Capital (“OpenGate”), a global private equity firm, announced today that it has signed a definitive agreement to acquire Maersk Training and its subsidiary Maersk H2S Safety Services. The company, a provider of global safety training and gas safety services, is being carved out from A.P. Møller - Mærsk A/S (MAERSK A:CPH), a listed integrated logistics company. Headquartered in Svendborg, Denmark, Maersk Training is a leading global provider of essential safety services that operates through two complementary business segments. The first segment, Maersk H2S Safety Services, is a specialist provider of outsourced hydrogen sulphide and Health, Safety and Environment safety services, which include onsite supervision, monitoring and safety equipment maintenance for customers in high-risk operating environments. The second segment, Training Business, is a global provider of safety training, competency development and simulation, delivered through instructor led, digital and virtual
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom